Stocks
KalVista Pharmaceuticals, Inc.KALV
NASDAQHealthcareBiotechnology$16.94-2.53%
A clinical-stage biotechnology company developing small‑molecule therapies for diseases driven by excessive protease activity, with a primary focus on hereditary angioedema (HAE). Its lead program, sebetralstat, is an oral plasma kallikrein inhibitor designed for on‑demand treatment of HAE attacks, ...
Market Cap: $856.3M52W Range: $9.23 – $19.00
Congressional Interest in KalVista Pharmaceuticals, Inc. (KALV)
1 member of Congress has disclosed 1 trade in KalVista Pharmaceuticals, Inc. (KALV), a Healthcare company. The buy/sell breakdown shows 1 purchase versus 0 sales, indicating net buying interest from lawmakers. All data is sourced from STOCK Act periodic transaction reports filed with Congress.
Total Disclosures
1
Unique Politicians
1
Buys
1
Sells
0
Who in Congress Is Trading KALV?
| Date | Politician | Type | Amount |
|---|---|---|---|
| 2022-12-12 | Christopher L. Jacobs | buy | $1K – $15K |